Brief: Morphosys' Says Phase 3 Study Of Pelabresib In Myelofibrosis Demonstrates Statistically Significant Improvement In Spleen Volume Reduction And Strong Positive Trend In Symptom Reduction

Morphosys AG

20/11/2023 21:30

Nov 20 (Reuters) - Morphosys Ag  MORG.DE :
    * EQS-ADHOC: AD HOC: MORPHOSYS’ PHASE 3 STUDY OF PELABRESIB
IN
MYELOFIBROSIS DEMONSTRATES STATISTICALLY SIGNIFICANT IMPROVEMENT
IN SPLEEN VOLUME REDUCTION AND STRONG POSITIVE TREND IN SYMPTOM
REDUCTION
    * MANIFEST-2 MET PRIMARY ENDPOINT,NEARLY DOUBLING SVR35
RESPONSE
RATE (66% VERSUS 35%)
    * MORPHOSYS INTENDS TO SUBMIT FOR APPROVAL IN U.S. AND
EUROPE IN
MID-2024
    * SAFETY RESULTS WERE CONSISTENT WITH PRIOR CLINICAL TRIALS,
WITH
NO NEW SAFETY SIGNALS
    * MORPHOSYS -SECONDARY ENDPOINTS ASSESSING SYMPTOM
REDUCTION,
TSS50& ABSOLUTE CHANGE IN TSS, SHOWED SIGNIFICANT IMPROVEMENTS
FOR INTERMEDIATE-RISK PATIENTS

Source text for Eikon:  ID:nEQ4hWgF1a 
Further company coverage:  MORG.DE 

 ((Reuters.Briefs@thomsonreuters.com;;))